{"filing":{"accession_number":"0001104659-26-075777","cik":"0001377121","ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618251d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/tm2618251d1_8k.htm"},"events":[{"id":11910,"run_id":10482,"accession_number":"0001104659-26-075777","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Protagonist Therapeutics held an Annual Meeting of Stockholders at which shareholders voted on four proposals: election of two Class I directors (Dinesh V. Patel and Lewis T. Williams), an advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as the independent auditor, and approval of the 2026 Equity Incentive Plan. Final voting results for all four proposals are disclosed.","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8622,"accession_number":"0001104659-26-075777","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Equity Incentive Plan, which replaces the 2016 Plan and authorizes issuance of equity awards (stock options, RSUs, restricted stock, and performance-based awards) to executives and employees. This is a compensatory arrangement disclosure under Item 5.02(e), material because it establishes the framework for future executive compensation and dilutes shareholders by authorizing up to 650,000 new shares plus carryover shares from the prior plan.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:34:02.315734+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8623,"accession_number":"0001104659-26-075777","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from an Annual Meeting covering four proposals: election of two Class I directors (Dinesh V. Patel and Lewis T. Williams), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of the 2026 Equity Incentive Plan. The filing presents final voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:34:02.315734+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8622,"accession_number":"0001104659-26-075777","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Equity Incentive Plan, which replaces the 2016 Plan and authorizes issuance of equity awards (stock options, RSUs, restricted stock, and performance-based awards) to executives and employees. This is a compensatory arrangement disclosure under Item 5.02(e), material because it establishes the framework for future executive compensation and dilutes shareholders by authorizing up to 650,000 new shares plus carryover shares from the prior plan.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:34:02.315734+00:00","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-06-18"},{"id":8623,"accession_number":"0001104659-26-075777","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from an Annual Meeting covering four proposals: election of two Class I directors (Dinesh V. Patel and Lewis T. Williams), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of the 2026 Equity Incentive Plan. The filing presents final voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:34:02.315734+00:00","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-06-18"}]}